Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
37.9M
-
Shares change
-
+1.05M
-
Total reported value, excl. options
-
$248M
-
Value change
-
+$6.77M
-
Number of buys
-
51
-
Number of sells
-
-60
-
Price
-
$6.55
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q4 2020
136 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q4 2020.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.9M shares
of 166M outstanding shares and own 22.9% of the company stock.
Largest 10 shareholders include BVF INC/IL (5.58M shares), BlackRock Inc. (3.81M shares), VANGUARD GROUP INC (2.93M shares), PERCEPTIVE ADVISORS LLC (2.58M shares), VICTORY CAPITAL MANAGEMENT INC (2.32M shares), RENAISSANCE TECHNOLOGIES LLC (2.06M shares), STATE STREET CORP (2.05M shares), RTW INVESTMENTS, LP (1.53M shares), FMR LLC (1.05M shares), and GEODE CAPITAL MANAGEMENT, LLC (758K shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.